Points clés de l’étude

Points clés de l’étude1

DOR/3TC/TDF=100 mg de doravirine, 300 mg de lamivudine et 300 mg de fumarate de ténofovir disoproxil;
EFV/FTC/TDF=600 mg d’éfavirenz, 200 mg d’emtricitabine et 300 mg de fumarate de ténofovir disoproxil

Bibliographie:

  1. Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
    (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
  2. Supplement to: Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

DZ-DOR-00009. Date d’expiration: 1-10-2026